XXXX with @entity3567 differentiation.

@entity1204 @entity1 @entity5 @entity3567
OBJECTIVE: To report a case of stage IIIc poorly differentiated @entity1204 with @entity3567 differentiation and to review previously reported cases. METHODS: The clinical course and histopathology of the case were reviewed, and a literature search for other reported cases was performed. RESULTS: The @entity5 contained syncytiotrophoblast-like giant cells that stained positively for the beta subunit of @entity1 chorionic gonadotropin (beta-hCG), and the patient's serum beta-hCG level was elevated (95 mIU/ml), but became undetectable after treatment. Beta-hCG was used as a @entity5 marker during further therapy. At 16 months' survival, she remains without evidence of disease and with a beta-hCG (level < 5 mIU/ml). Nine other cases of @entity3567 differentiation in gynecologic @entity5 have been reported, five in @entity1204 which we review. CONCLUSIONS: Trophoblastic differentiation in gynecologic @entity5 is rare. Beta-hCG may be useful as a @entity5 marker in these cases. The clinical behavior of these @entity5 has been aggressive, with advanced stages at diagnosis, early widespread metastases or recurrences and poor @entity1 outcomes. The @entity1 presented in this report, however, remains without evidence of disease 16 months following diagnosis and may be the longest survivor with this @entity5 reported to date.
